Your session is about to expire
← Back to Search
Inhaled Imatinib for Pulmonary Arterial Hypertension (IMPAHCT-FUL Trial)
IMPAHCT-FUL Trial Summary
This trial will study the long-term safety and effectiveness of a medicine, AV-101, for pulmonary arterial hypertension. Subjects will receive one of three doses until the optimal dose is found.
IMPAHCT-FUL Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.IMPAHCT-FUL Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You agreed to take part in the LTE and finished the placebo-controlled 24-week Study AV-101-002.
- Group 1: low dose AV-101
- Group 2: medium dose AV-101
- Group 3: high dose AV-101
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there any vacancies in this research project for volunteers?
"Affirmative. According to the info hosted on clinicaltrials.gov, this medical trial is actively recruiting patients from a single site since its posting date of November 2nd 2022 and most recent edit made on December 6th 2022. Currently, 462 participants are desired for the research project."
Does this research permit minors to participate?
"In order to meet the study's eligibility requirements, participants must have reached 18 years of age but not surpassed 75."
What is the largest number of participants accepted into this clinical experiment?
"Affirmative. Clinicaltrials.gov data supports the notion that recruiting is currently being conducted for this research study, which was initially posted on November 2nd 2022 and latest modified December 6th 2022. The trial requires 462 participants to be enrolled from 1 medical centre."
Is it possible for me to join this medical experiment?
"This clinical trial is recruiting 462 patients, who must meet the criteria of having pulmonary arterial hypertension and being between 18 to 75 years old."
Share this study with friends
Copy Link
Messenger